Cartesian raises $130M via PIPE; Phase 2b MG trial meets primary endpoint, 71% responder rate

Cartesian Therapeutics, Inc.

Raised ~$130M by selling 3.56M common shares and 2.94M Series B convertible preferred shares at $20 each.
Phase 2b trial of Descartes-08 in myasthenia gravis met primary endpoint: 71% of treated patients had ≥5-point MGC improvement vs 25% placebo (p=0.018).
Descartes-08 well tolerated with no cytokine release syndrome or neurotoxicity; supports outpatient administration without preconditioning chemo.
Appointed Kemal Malik, MBBS to Board; first patient dosed in Phase 2 SLE trial of Descartes-08.

item 1.01 item 5.03 item 3.02 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kemal Malik

Class II director

RNAC · Cartesian Therapeutics, Inc.

Effective: 2024-07-01
Filed: July 2, 2024, 7:59 PM ET

On July 1, 2024, the Board of Directors (the “Board”) of the Company appointed Kemal Malik, MBBS as a Class II director, and fixed the size of the Board at nine directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kemal Malik was appointed as Class II director at Cartesian Therapeutics, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

On July 1, 2024, the Board of Directors (the “Board”) of the Company appointed Kemal Malik, MBBS as a Class II director, and fixed the size of the Board at nine directors.

View on SEC.gov

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-032080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.